GlassScriptPhysician profile
Julie Applebaum
NPI 1861932204
$3,036.16
in general payments reported to CMS, 2019-2025
25 companies · $780 in 2025
The $780 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $855 · 2023: $220 · 2024: $1,181 · 2025: $780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,105 · Education: $75.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,105.15 |
| Education | $75.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $783.34 | 2022 | |
| Daiichi Sankyo INC. | $464.44 | 2022-2025 | Enhertu, Datroway |
| Alexion Pharmaceuticals, INC. | $405.05 | 2024-2025 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $214.53 | 2023-2025 | Tagrisso, Calquence, Fasenra |
| Merck Sharp & Dohme LLC | $204.83 | 2024-2025 | Keytruda |
| Pharmacosmos Therapeutics INC. | $140.15 | 2023-2024 | Monoferric |
| Glaxosmithkline, LLC. | $124.56 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Immunogen, INC. | $108.01 | 2024 | Elahere |
| Abbvie INC. | $68.17 | 2025 | |
| Novartis Pharmaceuticals Corporation | $61.16 | 2024-2025 | |
| Incyte Corporation | $53.96 | 2024-2025 | Jakafi |
| Janssen Biotech, INC. | $49.43 | 2024-2025 | Rybrevant, Tecvayli |
| Myriad Genetic Laboratories, INC. | $48.34 | 2023 | Precisetumor |
| Bayer Healthcare Pharmaceuticals INC. | $46.30 | 2025 | |
| Tersera Therapeutics LLC | $37.39 | 2025 | Zoladex |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $36.44 | 2024 | |
| Stemline Therapeutics INC. | $32.59 | 2025 | Orserdu |
| Emd Serono, INC. | $28.48 | 2023-2024 | Bavencio |
| Exelixis INC. | $22.63 | 2024 | Cabometyx |
| Takeda Pharmaceuticals U.S.A., INC. | $20.71 | 2025 | Iclusig |
| Eisai INC. | $19.94 | 2025 | |
| Geron Corporation | $16.98 | 2025 | Rytelo |
| Veloxis Pharmaceuticals, INC. | $16.77 | 2023 | Envarsus |
| Legend Biotech USA INC. | $16.65 | 2024 | |
| Tolmar, INC. | $15.31 | 2025 | Jatenzo, Eligard |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Applebaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.